Solitary pulmonary nodule
A rounded opacity up to 3 cm surrounded by aerated lung: how to tell benign from malignant and what to do next.
- A solitary pulmonary nodule (SPN) is a single, rounded opacity in the lung, up to 3 cm across, surrounded by normal aerated lung. Anything larger is a mass and is usually malignant.
- Most nodules are benign. The job is to estimate the probability of cancer from the nodule's size, density, margin, growth, site and the patient's age and smoking.
- Features that favour malignancy include size above 10 mm, spiculation, an upper lobe, solid or part-solid density, smoking and growth with a volume doubling time under 400 days.
- Management follows risk and nodule type: small or clearly benign nodules need no follow-up; others get computed tomography (CT) surveillance, positron emission tomography (PET-CT), biopsy or resection depending on risk.
- Fleischner follow-up intervals differ for solid and subsolid nodules, and screen-detected nodules are classified with Lung-RADS; both are separate from management of incidental nodules.
By the end of this page you should be able to:
- Define a solitary pulmonary nodule and state the size that separates it from a mass.
- List the common benign and malignant causes and the features that tilt the balance either way.
- Estimate the probability of malignancy qualitatively and name the most used risk models.
- Apply Fleischner 2017 follow-up intervals to solid, ground-glass and part-solid nodules.
- Choose between CT surveillance, PET-CT, biopsy and surgery from the nodule's risk and type.
- Quote current low-dose CT lung cancer screening criteria and interpret Lung-RADS management in broad terms.
- Adapt assessment and referral to low-resource settings where tuberculosis is common.
The 3 cm cut-off is radiological rather than biological. It separates a nodule, where watchful surveillance is reasonable, from a mass, where tissue diagnosis and staging are usually needed promptly. A nodule is a single lesion with no associated atelectasis, hilar enlargement or pleural effusion; several nodules raise different questions (metastases, infection, granulomatous disease).
Most nodules are found incidentally on a chest radiograph or CT done for another reason. Lung nodules are reported on roughly 2 to 24% of chest CT scans performed for other reasons, with a mean around 13%, and in roughly 17 to 53% of baseline scans in screening populations. [3]
Benign nodules are commoner than malignant ones in unselected populations. About 1.4% of incidentally detected and about 1.5% of screen-detected nodules are malignant; in referral practice the proportion is much higher. [3]
Benign nodules are dominated by old granulomatous infection and hamartoma. Common benign causes include infectious granulomas and hamartomas. [1] Autoimmune disease, particularly rheumatoid arthritis, and granulomatosis with polyangiitis are also associated with pulmonary nodules, and infection such as tuberculosis and histoplasmosis is a frequent cause where these are endemic. [2] Intrapulmonary (perifissural) lymph nodes are common benign incidental nodules and do not need follow-up even if their average diameter exceeds 6 mm. [2]
Common malignant causes are primary lung cancer, carcinoid tumours and metastases to the lung. [1] A metastasis is more likely in someone with known active cancer, and melanoma and sarcoma in particular spread to the lung. [3] A new lung primary can be more common than metastasis in patients with a solid malignancy elsewhere. [3]
| Category | Examples | Clues that point toward it |
|---|---|---|
| Benign infection | Tuberculoma, histoplasmosis | Travel or residence in endemic area, calcification diffuse/central/laminated, satellite nodules, positive skin or interferon-gamma release test; PET may be falsely positive [2][3] |
| Hamartoma | Pulmonary hamartoma | Popcorn calcification, fat attenuation, smooth lobulated border, youngish patient [1][3] |
| Autoimmune | Rheumatoid nodule, granulomatosis with polyangiitis | Joint disease, systemic vasculitis, multiple nodules, cavitation [2] |
| Intrapulmonary lymph node | Perifissural nodule | Triangular/lentiform, under 10 mm, smooth margins, pleural or fissural contact, no spiculation [2][4] |
| Primary lung cancer | Adenocarcinoma, squamous cell carcinoma, carcinoid | Smoking, age, upper lobe, spiculation, part-solid density, growth, intense PET uptake [1][2] |
| Metastasis | Melanoma, sarcoma, colorectal, renal | Known primary, lower lobe predominance, multiple rounded nodules, feeding vessel sign [1][3] |
No single feature proves anything; each feature changes the odds. The assessment combines them with patient risk factors.
| Feature | Favours benign | Favours malignant |
|---|---|---|
| Size | Under 5 mm: under 1% risk[1][2] | Over 10 mm: 33 to 60%; over 2 cm: 64 to 82%[1][2] |
| Margin | Smooth or polygonal (though up to a third of smooth nodules are malignant)[1][2] | Spiculated (sunburst); lobulated is intermediate[1][2] |
| Calcification | Diffuse, central, laminated or popcorn[1][2][3] | Stippled, eccentric, punctate or amorphous does not reassure[1][2][3] |
| Density and contents | Fat attenuation (minus 40 to minus 120 Hounsfield units) suggests hamartoma; thin smooth-walled cavity[2] | Sub-solid or part-solid nodule; thick irregular cavity wall[2] |
| Growth | Volume doubling time over 500 days (negative predictive value 98%); under 20 days suggests infection[2] | Doubling time of 20 to 400 days[2] |
| Site | Smooth perifissural or pleural-attached oval or triangular nodule (intrapulmonary lymph node)[1][2][4] | Upper lobe; pleural indentation, vascular convergence, bubble-like lucencies[1][2][4] |
| Enhancement | Under 15 Hounsfield units after contrast[2] | Over 20 Hounsfield units after contrast[2] |
Malignancy risk rises steeply with diameter. Nodules under 5 mm have under 1% risk of cancer; 5 to 10 mm nodules have a 6 to 28% chance; nodules above 10 mm have a 33 to 60% chance; and nodules above 2 cm have a 64 to 82% chance of cancer. [1][2]
A spiculated margin (the sunburst or corona radiata sign) carries the highest risk and has a positive predictive value of up to 90% for malignancy, although a few benign lesions can look spiculated. Smooth or polygonal margins favour benignity but up to one third of nodules with smooth margins are malignant; lobulated margins carry an intermediate risk. [1][2]
Calcification pattern is decisive. Diffuse, central, laminated or popcorn calcification is almost always benign, seen in granulomas and hamartomas. Stippled, eccentric, punctate or amorphous calcification does not reassure and can occur in cancers. [1][2][3]
Fat attenuation between minus 40 and minus 120 Hounsfield units suggests hamartoma. Cavitation with thin, smooth walls is usually benign, whereas thick irregular walls favour malignancy; about 95% of cavitary nodules with wall thickness above 15 mm are malignant. [2]
Sub-solid (ground-glass or part-solid) nodules are more likely to be malignant than solid ones of the same size, and persistent part-solid nodules with solid components above 6 mm are highly suspicious. [2]
Growth is assessed by volume doubling time (VDT): the time for the nodule to double its volume, noting that a 26% increase in diameter doubles the volume. Malignant solid nodules usually have a VDT of 20 to 400 days. Infection typically doubles in under 20 days. NELSON screening data showed malignancy risks of 0.8%, 4% and 9.9% for VDT above 600, 400 to 600 and under 400 days. A VDT above 500 days has a reported negative predictive value for malignancy of 98%. [2]
Upper lobe location is an independent risk factor for cancer. Nodules with bubble-like lucencies, pleural indentation, vascular convergence, lobulation or an irregular air bronchogram lean malignant. Perifissural and pleural-attached nodules with smooth oval or triangular morphology are almost always benign intrapulmonary lymph nodes. [1][2][4]
A nodule that enhances more than 20 Hounsfield units after intravenous contrast is usually malignant, while enhancement below 15 Hounsfield units favours benignity. [2]
PET-CT separates the two better: in retrospective data on nodules 7 to 30 mm, sensitivities for CT, PET and PET-CT were 93%, 69% and 97%, with specificities of 31%, 85% and 85%. PET fails in small tumours under 7 to 10 mm and in low-metabolism tumours such as adenocarcinoma in situ and carcinoid, and is false-positive in infection and inflammation. [2]
Age, smoking, prior malignancy, family history of lung cancer, emphysema and exposure to asbestos, silica or radon all raise the probability of cancer. Imaging features overlap heavily, so no single benign-looking feature and no single scan can rule cancer out. [1][2]
Most experienced clinicians classify the pre-test probability of malignancy as low, under 5%, intermediate, 5 to 65%, or high, above 65%. This drives what happens next, especially for nodules above 8 mm. [2]
| Factor | Lower risk | Higher risk |
|---|---|---|
| Nodule diameter | Under 5 mm: under 1%; 5 to 10 mm: 6 to 28%[1][2] | Over 10 mm: 33 to 60%; over 2 cm: 64 to 82%[1][2] |
| Margin | Smooth[1][2] | Spiculated[1][2] |
| Location | Elsewhere in the lung[1] | Upper lobe[1][2] |
| Patient | Younger, never-smoker, no prior cancer[1][2] | Older, smoker, prior cancer, family history, emphysema, asbestos, silica or radon exposure[1][2] |
| Overall pre-test probability | Low: under 5%[2] | Intermediate: 5 to 65%; high: above 65%[2] |
Three models are in common use. The Mayo Clinic model uses age, smoking, history of extrathoracic cancer, nodule diameter, spiculation and upper-lobe location. The Veterans Affairs model is another widely used model for estimating pre-test probability. The Brock University model was built and validated in screened, high-risk smokers and may over-estimate cancer risk when applied to incidental nodules in never-smokers. The Herder modification adds PET findings to the Mayo model and raises its discrimination. [1][2][3]
No model is clearly superior, and all predicted probabilities are similar to expert clinical judgement. A risk calculator should support, not replace, that judgement. [2][3]
Every nodule needs three questions answered: is it clearly benign, is its risk low enough for surveillance, or is it high enough to sample or remove?
Approach to an incidental pulmonary nodule in an adult
- Incidental pulmonary nodule found on CTSingle, well-defined, up to 3 cm, surrounded by aerated lung; no effusion or hilar enlargement
- Compare with prior imaging and clinical historyStable for 2 years or benign calcification/fat or perifissural lymph node: stop here
- Question: Nodule type?
Solid nodule
- Question: Average diameter (Fleischner 2017)?
Under 6 mm
- Low risk: no routine follow-up; high risk: optional CT at 12 months
6 to 8 mm
- CT at 6 to 12 months, then consider CT at 18 to 24 months (high risk: two follow-up studies)
Above 8 mm
- Estimate probability of malignancy with clinical judgement or a validated modelLow under 5%, intermediate 5 to 65%, high above 65%
- Low risk: CT surveillance; intermediate: PET-CT and/or biopsy; high risk: surgical resection or non-surgical treatment
Pure ground-glass nodule
Part-solid nodule
Multiple nodules
- Follow the most suspicious nodule; Fleischner gives separate intervals for multiple solid and subsolid nodules
- Proceed to CT surveillance, PET-CT or tissue diagnosis according to risk and fitnessRepeat imaging with the same protocol and thickness each time
Fleischner Society 2017 guidance forms the basis of the solid nodule intervals above, and also sets the ground-glass and part-solid follow-up. [2][3]
PET-CT is used for solid nodules above 8 mm when the probability of cancer is intermediate. It changes management in two ways: an intensely avid nodule supports tissue diagnosis, and a negative scan in a high-risk patient does not exclude cancer. [2] PET is less accurate in regions with a high prevalence of tuberculosis and histoplasmosis, where granulomas light up, and falsely negative in mucinous, lepidic adenocarcinoma and carcinoid. [3]
Herder and BTS practice use PET uptake to recalculate risk. On a Herder-type scale, absent or faint uptake argues for surveillance; moderate or intense uptake supports biopsy or treatment. BTS guidance recommends PET-CT for nodules at or above 8 mm (or 300 mm3) with risk above 10%, and advises that intermediate Herder scores of 10 to 70% are biopsied or watched according to patient wishes, while scores above 70% are biopsied or treated. [3]
Tissue is needed when CT morphology and PET do not settle the question, or when the probability of cancer is high enough that a tissue diagnosis changes management.
- CT-guided transthoracic needle biopsy is the most available modality, with sensitivity around 91% and specificity around 94 to 97%. False negatives average 10 to 22%, so a negative, non-diagnostic or "benign" result in a high-probability nodule does not rule out cancer and needs a repeat or surgical diagnosis. Pneumothorax occurs in about 15% of cases, with a chest tube needed in about 6%, and bleeding in about 1%. [2][3]
- Conventional bronchoscopy has a lower yield, about 14 to 53% for peripheral lesions and under 35% for nodules under 2 cm. Radial endobronchial ultrasound gives about 71% yield, electromagnetic navigation about 65%, virtual bronchoscopy about 73%, and combined navigation with radial ultrasound about 88% in small studies. [2][3]
- Surgical resection (video-assisted thoracoscopic wedge resection with frozen section, progressing to lobectomy if malignant) remains the gold standard when the lesion is high risk or the diagnosis remains uncertain. [2]
- Stereotactic body radiotherapy is the option for confirmed or strongly suspected stage I disease in patients who cannot have surgery. [2]
Before operating, assess cardiac risk, spirometry and transfer factor. A predicted post-operative FEV1 or DLCO below 60% of predicted warrants formal exercise testing. [2]
Screening is a separate pathway from incidental nodule follow-up. In the United States, the 2021 USPSTF recommendation offers annual low-dose CT to people aged 50 to 80 years with at least 20 pack-years of smoking who currently smoke or quit within the past 15 years. [5] Eligibility starts at age 50 rather than 55 and at 20 rather than 30 pack-years, which widened eligibility. [5]
Screen-detected nodules are classified with Lung-RADS, not Fleischner. Lung-RADS 2022 expanded Category 0 to include suspected infectious or inflammatory findings with 1 to 3 month follow-up, gave stepped management (stable Category 3 becomes Category 2, stable 4A becomes 3), extended perifissural-type benign criteria to all juxtapleural solid nodules of 10 mm or less, defined significant growth as an increase of more than 1.5 mm within 12 months, and removed the malignancy-percentage column from the table. [4] Juxtapleural nodules that are solid, smooth, 10 mm or less and oval, lentiform or triangular remain Category 2. [4]
Tuberculosis is a common masquerader. In high-prevalence regions most nodules may be granulomas, and calcification in diffuse, central or laminated patterns is typical of old tuberculosis or histoplasmosis. [3] A practical approach is to obtain a travel and exposure history, a tuberculin or interferon-gamma release test, and to remember that PET is often falsely positive in granulomatous disease. [2][3]
When CT surveillance, PET or guided biopsy is unavailable, rely on clinical probability and what imaging exists: a clear benign calcification pattern, a perifissural lymph node or a stable 2-year-old film avoids further work. Where imaging is limited, follow indeterminate nodules with repeat low-dose, thin-section, unenhanced CT rather than high-resolution CT, and refer early to a centre with biopsy or surgery when risk is high and the patient is fit. [1][2] Fleischner guidance applies to incidentally detected nodules in adults aged 35 and over; children, immunocompromised patients and known cancer patients need case-by-case decisions. [1][2]
Refer urgently when the probability of cancer is high, above 65%, when the nodule is growing, or when the patient is a surgical candidate and the non-surgical work-up cannot exclude cancer. Patients with a recent embolus or stroke-like deficit and no source also need specialist review. [2]
- A solitary pulmonary nodule is a single, rounded opacity up to 3 cm surrounded by aerated lung; larger lesions are masses and usually malignant.
- Most nodules are benign, but malignancy risk rises from under 1% below 5 mm to 33 to 60% above 10 mm and 64 to 82% above 2 cm.
- Benign causes include infectious granulomas (often tuberculosis or histoplasmosis), hamartoma, intrapulmonary lymph nodes, infection and rheumatoid nodules; malignant causes are primary lung cancer, carcinoid and metastasis.
- Features favouring malignancy include spiculation, part-solid density, upper lobe location, smoking, age and a volume doubling time of 20 to 400 days.
- Benign calcification (diffuse, central, laminated or popcorn), fat and a perifissural position reassure, but stippled or eccentric calcification does not.
- Models (Mayo, Veterans Affairs, Brock, Herder) estimate probability of malignancy; Brock was built for screened smokers and may over-estimate risk in never-smokers.
- CT surveillance, PET-CT and biopsy follow an intermediate pathway; high risk in a fit patient leads to surgical resection.
- CT-guided biopsy is about 91% sensitive and 94 to 97% specific, with pneumothorax in about 15%.
- Fleischner 2017 intervals are 6 to 12 months and 18 to 24 months for solid nodules of 6 to 8 mm, immediate CT at 3 months, PET-CT or biopsy above 8 mm, 6 to 12 months then every 2 years for ground-glass nodules, and 3 to 6 months then annual follow-up for part-solid nodules.
- USPSTF 2021 offers annual low-dose CT to adults 50 to 80 years with at least 20 pack-years who currently smoke or quit within 15 years.
- Screen-detected nodules use Lung-RADS; incidentally detected nodules use Fleischner or BTS guidance.
- In high-tuberculosis areas, calcification pattern, endemic infection, negative PET interpretation and sensible referral keep assessment safe.
Answer each one in your head first, then open the answer.
What is the size cut-off that separates a solitary pulmonary nodule from a lung mass?
Show answerHide answer
A solitary pulmonary nodule measures up to 3 cm; lesions above 30 mm are lung masses and are usually malignant. The cut-off is radiological, and a single nodule has no associated effusion or hilar enlargement.
A 65-year-old smoker has an 11 mm solid nodule in the right upper lobe with a spiculated margin. What is the likely probability of malignancy and the next step?
Show answerHide answer
Size above 10 mm carries a 33 to 60% risk and upper-lobe, spiculated nodules sit at the high end; combined, this patient is high probability. The next step is surgical diagnosis or anatomic resection in a fit patient, or PET-CT plus biopsy if confirmation is needed; CT surveillance alone is inappropriate.
Why does a nodule with smooth margins and no calcification still need follow-up?
Show answerHide answer
Smooth or polygonal margins occur in benign nodules but also in about one third of malignant nodules, and absence of calcification does not reassure. Size, growth, site and patient risk must be combined, and an interval scan demonstrates benign stability.
Which Fleischner 2017 interval applies to a single solid 7 mm nodule in a high-risk patient?
Show answerHide answer
CT at 6 to 12 months, followed by CT at 18 to 24 months: two follow-up studies. In a low-risk patient a single study at 6 to 12 months with a further 18 to 24 month scan if uncertainty remains is acceptable.
When is PET-CT unhelpful even when a nodule looks malignant?
Show answerHide answer
PET-CT has limited value for nodules under 7 to 10 mm, for low-metabolism tumours such as carcinoid and adenocarcinoma in situ, and in regions with endemic tuberculosis or histoplasmosis, where granulomas light up. A negative PET does not exclude cancer in a high-risk patient.
A 55-year-old man with 35 pack-years presents for lung health. What screening should he be offered and how will a small nodule found on that scan be managed?
Show answerHide answer
Annual low-dose CT under USPSTF 2021 criteria (age 50 to 80, at least 20 pack-years, current or recent smoker). Screen-detected nodules are classified with Lung-RADS, with surveillance and escalation thresholds set for that population, not the Fleischner intervals used for incidental nodules.
Pneumoconiosis; interstitial lung disease; hypersensitivity pneumonitis; lung cancer; pulmonary hypertension; bronchiectasis; pleural effusion; sarcoidosis; eosinophilic pulmonary syndromes; tuberculosis; cough; haemoptysis; chest imaging; bronchoscopy.
Lung cancer
Lung cancer from first suspicion to treatment by stage: risks, types, presentation, staging, molecular tests, and care in low-resource settings.Pneumoconioses
Inhaled workplace dusts that scar the lungs: what silicosis, coal disease, asbestosis, beryllium disease, and byssinosis are, and how they differ.Sarcoidosis
A multisystem granulomatous disease: how noncaseating granulomas form, how sarcoidosis presents by organ, and how it is diagnosed and treated.
Another topic links here.
- Khan AN, Al-Jahdali HH, Irion KL, Arabi M, Koteyar SS. Solitary pulmonary nodule: A diagnostic algorithm in the light of current imaging technique. Avicenna J Med 2011;1(2):39-51. Accessed .
- Khan T, Usman Y, Abdo T, Chaudry F, Keddissi JI, Youness HA. Diagnosis and management of peripheral lung nodule. Ann Transl Med 2019;7(15):348. Accessed .
- McNulty W, Baldwin D. Management of pulmonary nodules. BJR Open 2019;1:20180051. Accessed .
- Petranovic M, Prosper AE, Hunsaker AR, Lam S, Christensen JD. ACR lung-RADS: updates and future directions. Cancer Imaging 2026;26:147. Accessed .
- Yell N, Eberth JM, Alberg AJ, et al. Comparison of the characteristics of the population eligible for lung cancer screening under 2013 and population newly eligible under 2021 US Preventive Services Task Force recommendations. Cancer Causes Control 2024;35(9):1233-1243. Accessed .
Educational content for medical students and doctors. It is not a substitute for clinical judgement or local guidelines.